Scarica l'app Stockscreener
1.11
4.72%
0.05
Dopo l'orario di chiusura:
1.10
-0.01
-0.90%
Mira Pharmaceuticals Inc Borsa (MIRA) Ultime notizie
MIRA completes Phase 1 trial of oral NMDA drug Ketamir-2 - Investing.com
Investment Report: How does MIRA Pharmaceuticals Inc compare to its peersPortfolio Gains Report & Weekly High Return Stock Opportunities - baoquankhu1.vn
MIRA Technical Analysis & Stock Price Forecast - Intellectia AI
Mira Pharmaceuticals Inc (K6S.MU) stock price, news, quote and history - Yahoo Finance UK
MIRA Pharmaceuticals (MIRA) CEO granted 83,500 RSUs - Stock Titan
MIRA Stock Price, Quote & Chart | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA Should I Buy - Intellectia AI
Cash strain and trial progress at MIRA Pharmaceuticals (NASDAQ: MIRA) - Stock Titan
Mira Pharmaceuticals 10-K: $— Revenue, $(1.35) EPS, $(10.44)M Net Loss - tradingview.com
MIRA Pharmaceuticals | 10-K: FY2025 Annual Report - Moomoo
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
What's going on with MIRA Pharma stock Tuesday? - MSN
Institution Moves: Can MIRA Pharmaceuticals Inc deliver alphaWeekly Gains Summary & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Analyst Downgrade: What are MIRA Pharmaceuticals Incs recent SEC filings showing2026 WrapUp & Community Shared Stock Ideas - baoquankhu1.vn
Retail Surge: Is MIRA Pharmaceuticals Inc a strong growth stockMarket Growth Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
MIRA Pharmaceuticals, Inc.Common Stock (NQ:MIRA) - FinancialContent
What's Going On With MIRA Pharma Stock Tuesday? - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
MIRA Pharmaceuticals Highlights Encouraging Safety Data for Mira-55 - TipRanks
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies - The Desert Sun
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Mira Pharmaceuticals, Inc. Announces Positive Preclinical Results for Mira-55, a Non-Opioid Pain and Anxiety Treatment - Minichart
Mira Pharmaceuticals reports preclinical results for Mira-55 with no observed THC- or rimonabant-like CNS side effects - Investing.com India
MIRA’s Mira-55 shows no CNS side effects in preclinical tests - investing.com
MIRA’s Mira-55 shows no CNS side effects in preclinical tests By Investing.com - Investing.com UK
MIRA Pharmaceuticals (MIRA) posts Mira-55 CNS and pain preclinical data - Stock Titan
MIRA pain drug showed morphine-like relief without THC-like effects - Stock Titan
Aug EndMonth: What is the Moat Score of MIRA Pharmaceuticals Inc2026 Macro Moves & Weekly Return Optimization Plans - baoquankhu1.vn
Momentum Shift: Can MIRA Pharmaceuticals Inc maintain its current growth rateRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Macro Review: Can MIRA Pharmaceuticals Inc maintain its current growth rateTrade Ideas & Reliable Price Breakout Signals - baoquankhu1.vn
Dividend Watch: Can MIRA Pharmaceuticals Inc deliver alphaQuarterly Profit Report & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Short Interest in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Drops By 13.9% - MarketBeat
MIRA Pharmaceuticals Inc. (MIRA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Ideas: What is the Moat Score of MIRA Pharmaceuticals IncTrade Exit Summary & Entry Point Confirmation Signals - baoquankhu1.vn
MIRA Pharmaceuticals completes dosing in Ketamir-2 Phase I trial - MSN
Wall Street Recap: What are MIRA Pharmaceuticals Incs recent SEC filings showing2025 Historical Comparison & Weekly High Return Stock Forecasts - baoquankhu1.vn
Winners Losers: Can MIRA Pharmaceuticals Inc deliver alphaQuarterly Risk Review & Step-by-Step Trade Execution Guides - baoquankhu1.vn
MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2 - ACCESS Newswire
MIRA tests oral Ketamir-2 for chemo nerve pain after safe Phase 1 - Stock Titan
MIRA Pharmaceuticals, Inc. (MIRA) Competitors - Meyka
MIRA Completes Phase 1 Trial of Ketamir-2 Therapy - TipRanks
Mira Pharmaceuticals Inc completes phase 1 dosing of Ketamir-2SEC filing - marketscreener.com
Mira Pharmaceuticals IncCompletes Phase 1 Dosing Of Ketamir-2SEC Filing - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) finishes Ketamir-2 Phase 1 dosing with encouraging safety - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 29.4% in February - MarketBeat
Ideas Watch: How does MIRA Pharmaceuticals Inc compare to its peersPortfolio Risk Summary & Verified Momentum Stock Watchlist - baoquankhu1.vn
Risk Analysis: What is the Moat Score of MIRA Pharmaceuticals IncWeekly Earnings Recap & Real-Time Price Movement Reports - baoquankhu1.vn
MIRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aug Summary: What are MIRA Pharmaceuticals Incs recent SEC filings showingJuly 2025 Opening Moves & Safe Capital Investment Plans - baoquankhu1.vn
MIRA Pharmaceuticals board approves SKNY Pharmaceuticals acquisition; combined value tops $60M - MSN
MIRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
What is MIRA Pharmaceuticals Inc. s revenue forecastEarnings Overview Report & Daily Price Action Insights - mfd.ru
MIRA PE Ratio & Valuation, Is MIRA Overvalued - Intellectia AI
What are MIRA Pharmaceuticals Inc.’s recent SEC filings showingPortfolio Value Summary & High Conviction Buy Zone Alerts - mfd.ru
0.81%
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):